Pimavanserin tartrate (ACP-103)

DRUG4 trials

Sponsors

ACADIA Pharmaceuticals Inc.

Conditions

Parkinson's Disease Psychosis

Phase 2

An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients

CompletedNCT01518309

ACADIA Pharmaceuticals Inc.Parkinson's Disease Psychosis

Start: 2004-11-17End: 2013-05-02Updated: 2020-11-23

Phase 3

A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

CompletedNCT00477672

ACADIA Pharmaceuticals Inc.Parkinson's Disease Psychosis

Start: 2007-06-30End: 2009-07-31Updated: 2017-05-17

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

CompletedNCT00550238

ACADIA Pharmaceuticals Inc.Parkinson's Disease Psychosis

Start: 2007-07-31End: 2018-05-30Updated: 2019-06-24

A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

CompletedNCT00658567

ACADIA Pharmaceuticals Inc.Parkinson's Disease Psychosis

Start: 2008-03-31End: 2009-12-31Updated: 2017-05-19

Related Papers

Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis

Frontiers in Neurology2022-10-0513 citations